ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

848
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Insights

Top 10 AI Applications Transforming Pharmaceutical Market Access

Executive Summary Market access has become one of the most strategically important functions within the pharmaceutical industry. Securing regulatory approval...
Insights

The Future of Scientific Engagement in an AI-Driven World

Executive Summary Scientific engagement is undergoing one of the most significant transformations in its history. For decades, scientific exchange in the...
Clinical

cAMPfield Plans Mid-Stage Ulcerative Colitis and Crohn’s Disease Trials for Prifemilast

cAMPfield Therapeutics is preparing to advance prifemilast, an oral phosphodiesterase type 4 (PDE4) inhibitor, into mid-stage clinical testing for...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you